Copyright
©The Author(s) 2020.
World J Clin Oncol. Aug 24, 2020; 11(8): 510-527
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.510
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.510
Table 2 Hypofractionated radiotherapy for locally-advanced non-small cell lung cancer
| Study | CT | Fx | Dose | Time | EQD-210 | HDV | Comments |
| Soccar trial Randomized, Phase II[41] | Sequential; Concomitant | 20 × 2.75 Gy | 55 Gy | 26 d | 58.4 Gy | Lungs-GTV: V20 < 35%; MLD < 18 Gy; Spinal cord: Dmax 44 Gy; Esophagus: D1 cc < 55 Gy; Heart: | High concomitant toxicity; CT adjusted dose required; Not compared vs standard (60 Gy); Widely used in United Kingdom |
| Anderson, Retrospective[42] | Sequential | 15 × 3 Gy | 45 Gy | 19 d | 48,7 Gy | Not published | Retrospective comparison; Similar results to standard: 30 × 2 (60 Gy) |
| Toronto Retrospective[43]; Anderson Randomized, Phase III[45] | Sequential | 15 × 4 Gy | 60 Gy | 19 d | 70 Gy | Lungs-GTV: V20 < 30%; V5 < 60%; MLD < 20 Gy; Spinal cord: Dmax 38 Gy; Esophagus: Dmax < 50 Gy; V45 < 10cc; Heart y MBV: Dmax < 63 Gy; V57 < 10 cc; Trachea y MB: Dmax < 63 Gy; V57 < 10 cc; Rib: Dmáx < 63 Gy; V30 < 30 cc; Brachial plexus: Dmax < 50 Gy; Skin < 50 Gy | Used for SBRT; Lack of data in stage III; Phase III RCT; 15 × 4 vs 30 × 2; Final results not published |
- Citation: Couñago F, Navarro-Martin A, Luna J, Rodríguez de Dios N, Rodríguez A, Casas F, García R, Gómez-Caamaño A, Contreras J, Serrano J. GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World J Clin Oncol 2020; 11(8): 510-527
- URL: https://www.wjgnet.com/2218-4333/full/v11/i8/510.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i8.510